Nucl Med Mol Imaging.  2019 Oct;53(5):313-319. 10.1007/s13139-019-00614-w.

Molecular Imaging in Breast Cancer

• Miladinova D

• KMID: 2465866
• DOI: http://doi.org/10.1007/s13139-019-00614-w

Abstract

Breast cancer (BC) is themost common cancer among females withmore than 2 million new cases diagnosed worldwide in 2018. Although the prognosis in the majority of cases in the early stages combined with appropriate treatment is positive, there are still about 30% of patients who will develop locoregional diseases and distant metastases. Molecular imaging is very important in the diagnosis, staging, follow-up, and radiotherapy planning. Additionally, it is useful in characterizing lesions, prognosis, and therapy response in BC patients. Nuclear medicine imaging modalities (SPECT and PET) are of indispensable importance in diagnosis (positron emission mammography), staging (sentinel lymph node detection), and follow-up with ¹â¸F-FDG and tumor characterization. Among many available PET tracers, the most commonly used are ¹â¸F-FLT, ¹â¸F-FES, ¹â¸F-FDHT, ⁶⁴Cu DOTA trastuzumab (bevacizumab), ⁶⁸Ga-PSMA, ⁶⁸Ga-RM2 (gastrin-releasing peptide receptor), ¹â¸F-fluorooctreotide (SSTR), and ⁶⁸Ga-TRAP (RGD)-3αvβ3-integrin. Molecular imaging helps in evaluation of tumor heterogeneity, allowing a shift from one-size-fits-all-approach to era of personalized medicine and precision oncology.

Keyword

Breast cancer; Molecular imaging; Positron emission tomography; Personalized medicine; Precision oncology

MeSH Terms

Breast Neoplasms*
Breast*
Diagnosis
Female
Follow-Up Studies
Humans
Lymph Nodes
Molecular Imaging*
Neoplasm Metastasis
Nuclear Medicine
Population Characteristics
Positron-Emission Tomography
Precision Medicine
Prognosis
Radiotherapy
Trastuzumab
Trastuzumab